Leukocare signs cooperation agreement with Sterigenics
Companies to develop new sterilisation procedures for biotherapeutics
Leukocare, a German developer of life science technologies, has signed a cooperation agreement with US-based Sterigenics, a contract sterilisation services provider.
The company has also closed a €1.6m financing round with its existing investors and the German bank KfW, which it says paves the way for the next stages in its development.
As part of the cooperation agreement Leukocare, a spin-off from Frankfurt University based in Martinsried near Munich, plans to use its stabilising and protecting solutions (SPS) technology with Sterigenics’ irradiation expertise to establish new sterilisation procedures for biotherapeutics.
The partnership aims to improve the sterility and security of patients receiving biotherapeutics, as well as simplifying production processes and cutting costs.
Leukocare says SPS technology combines the stabilising and protecting properties required for shelf life extension and radiation protection in one single product.
The technology is used to couple, protect and elute biofunctional molecules. The company can functionalise a variety of surfaces including implants, wound dressings, patches, stents, catheters and columns for ex-vivo blood treatment.
Sterigenics International is a portfolio company of Silverfleet Capital and PPM America Capital Partners. Headquartered in Oak Brook, Illinois, US, the firm offers technology in all leading sterilisation methods, including: gamma, ethylene oxide, electron beam and X-ray.
